Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS

Abstract

Background:

Imaging biomarkers of progressive multiple sclerosis (MS) are needed. Quantitative gradient recalled echo (qGRE) magnetic resonance imaging (MRI) evaluates microstructural tissue damage in MS.

Objective:

To evaluate qGRE-derived R2t* as an imaging biomarker of MS progression compared with atrophy and lesion burden.

Methods:

Twenty-three non-relapsing progressive MS (PMS), 22 relapsing-remitting MS (RRMS), and 18 healthy control participants underwent standard MS physical and cognitive neurological assessments and imaging with qGRE, FLAIR, and MPRAGE at 3T. PMS subjects were tested clinically and imaged every 9 months over 45 months. Imaging measures included lesion burden, atrophy, and R2t* in cortical gray matter (GM), deep GM, and normal-appearing white matter (NAWM). Longitudinal analysis of clinical performance and imaging biomarkers in PMS subjects was conducted via linear models with subject as repeated, within-subject factor. Relationship between imaging biomarkers and clinical scores was assessed by Spearman rank correlation.

Results:

R2t* reductions correlated with neurological impairment cross-sectionally and longitudinally. PMS patients with clinically defined disease progression (N = 13) showed faster decrease of R2t* in NAWM and deep GM compared with the clinically stable PMS group (N = 10). Importantly, tissue damage measured by R2t* outperformed lesion burden and atrophy as a biomarker of progression during the study period.

Conclusion:

qGRE-derived R2t* is a potential imaging biomarker of MS progression.

Keywords

Quantitative gradient recalled echo MRI non-relapsing progressive multiple sclerosis multiple sclerosis progression tissue damage imaging biomarker deep gray matter

Get full access to this article

View all access options for this article.

References

McDonald

Compston

Edan

, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

Dalton

Brex

Miszkiel

, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003; 53: 673–676.

Brex

Ciccarelli

O’Riordan

, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–164.

Sormani

Bruzzi

. MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013; 12(7): 669–676.

Lassmann

van Horssen

Mahad

. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647–656.

Dutta

Trapp

. Relapsing and progressive forms of multiple sclerosis: Insights from pathology. Curr Opin Neurol 2014; 27: 271–278.

Moccia

de Stefano

Barkhof

. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler 2017; 23(12): 1614–1626.

Ontaneda

Azevedo

, et al. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS. Neurology 2019; 92: 519–533.

Luo

Jagadeesan

Cross

, et al. Gradient echo plural contrast imaging: Signal model and derived contrasts: T2*, T1, phase, SWI, T1f, FST2*and T2*-SWI. NeuroImage 2012; 60: 1073–1082.

10.

Luo

Yablonskiy

Hildebolt

, et al. Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions. Mult Scler 2014; 20(3): 349–355.

11.

Sati

Cross

Luo

, et al. In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique. Neuroimage 2010; 51: 1089–1097.

12.

Ulrich

Yablonskiy

. Separation of cellular and BOLD contributions to T2* signal relaxation. Magn Reson Med 2016; 75(2): 606–615.

13.

Wen

Cross

Yablonskiy

. On the role of physiological fluctuations in quantitative gradient echo MRI: Implications for GEPCI, QSM, and SWI. Magn Reson Med 2015; 73(1): 195–203.

14.

Yablonskiy

Sukstanskii

Luo

, et al. Voxel spread function method for correction of magnetic field inhomogeneity effects in quantitative gradient-echo-based MRI. Magn Reson Med 2013; 70(5): 1283–1292.

15.

Wen

Goyal

Astafiev

, et al. Genetically defined cellular correlates of the baseline brain MRI signal. Proceedings of the National Academy of Sciences 2018; 115: E9727–E9736.

16.

Xiang

Wen

H-C

, et al. In vivo evolution of biopsy-proven inflammatory demyelination quantified by R2t* mapping. Ann Clin Transl Neurol 2020; 7(6): 1055–1060.

17.

Wen

Yablonskiy

Salter

, et al. Limbic system damage in MS: MRI assessment and correlations with clinical testing. PLoS ONE 2017; 12(11): e0187915.

18.

Xiang

Wen

Cross

, et al. Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis. J Magn Reson Imaging 2019; 49(2): 487–498.

19.

Fischer

Rudick

Cutter

, et al. The Multiple Sclerosis Functional Composite measure (MSFC): An integrated approach to MS clinical outcome assessment. Mult Scler 1999; 5(4): 244–250.

20.

Fox

Coffey

Conwit

, et al. Phase 2 trial of Ibudilast in progressive multiple sclerosis. N Engl J Med 2018; 379: 846–855.

21.

Fischl

. FreeSurfer. NeuroImage 2012; 62: 774–781.

22.

Brier

Snyder

Tanenbaum

, et al. Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Ann Clin Transl Neurol 2021; 8(5): 1096–1109.

23.

Benjamini

Hochberg

. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc: Ser B (Methodol) 1995; 57: 289–300.

24.

Tibshirani

. Regression shrinkage and selection via the Lasso. J Royal Stat Soc: Ser B (Methodol) 1996; 58: 267–288.

25.

Brownlee

Altmann

Prados

, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain: J Neurol 2019; 142: 2276–2287.

26.

Moll

Rietsch

Thomas

, et al. Multiple sclerosis normal-appearing white matter: Pathology–imaging correlations. Ann Neurol 2011; 70(5): 764–773.

27.

Lassmann

. Multiple sclerosis pathology. Cold Spr Harbor Persp Med 2018; 8: a028936.

28.

Sotirchos

Gonzalez-Caldito

Dewey

, et al. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Mult Scler J 2019; 26: 312–321.

29.

Pontillo

Cocozza

Lanzillo

, et al. Determinants of deep gray matter atrophy in multiple sclerosis: A multimodal MRI study. AJNR: Am J Neuroradiol 2019; 40(1): 99–106.

30.

Moll

Rietsch

Thomas

, et al. Multiple sclerosis normal-appearing white matter: Pathology-imaging correlations. Ann Neurol 2011; 70(5): 764–773.

31.

Yablonskiy

Wen

Kothapalli

SVVN

, et al. In vivo evaluation of heme and non-heme iron content and neuronal density in human basal ganglia. NeuroImage 2021; 235: 118012.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.44 MB